全文获取类型
收费全文 | 686篇 |
免费 | 34篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 33篇 |
妇产科学 | 5篇 |
基础医学 | 130篇 |
口腔科学 | 3篇 |
临床医学 | 46篇 |
内科学 | 25篇 |
皮肤病学 | 4篇 |
神经病学 | 36篇 |
特种医学 | 6篇 |
外科学 | 16篇 |
综合类 | 40篇 |
预防医学 | 287篇 |
药学 | 80篇 |
中国医学 | 8篇 |
肿瘤学 | 4篇 |
出版年
2023年 | 8篇 |
2022年 | 14篇 |
2021年 | 22篇 |
2020年 | 33篇 |
2019年 | 22篇 |
2018年 | 26篇 |
2017年 | 9篇 |
2016年 | 17篇 |
2015年 | 18篇 |
2014年 | 27篇 |
2013年 | 39篇 |
2012年 | 39篇 |
2011年 | 36篇 |
2010年 | 21篇 |
2009年 | 28篇 |
2008年 | 23篇 |
2007年 | 27篇 |
2006年 | 17篇 |
2005年 | 20篇 |
2004年 | 18篇 |
2003年 | 12篇 |
2002年 | 8篇 |
2001年 | 20篇 |
2000年 | 11篇 |
1999年 | 13篇 |
1998年 | 9篇 |
1997年 | 12篇 |
1996年 | 12篇 |
1995年 | 10篇 |
1994年 | 12篇 |
1993年 | 9篇 |
1992年 | 11篇 |
1991年 | 10篇 |
1990年 | 8篇 |
1989年 | 4篇 |
1988年 | 8篇 |
1987年 | 13篇 |
1986年 | 4篇 |
1985年 | 10篇 |
1984年 | 5篇 |
1983年 | 6篇 |
1981年 | 8篇 |
1980年 | 3篇 |
1979年 | 8篇 |
1978年 | 4篇 |
1977年 | 6篇 |
1976年 | 4篇 |
1975年 | 3篇 |
1974年 | 3篇 |
1973年 | 10篇 |
排序方式: 共有725条查询结果,搜索用时 15 毫秒
721.
The Public Health Agency of Sweden carried out a literature review on diphtheria vaccinations for seronegative people above 6 years of age with an uncertain vaccine history. The aim was to harmonise national Swedish recommendations with the current World Health Organization recommendations. There was no firm conclusion about dosage. Some low-dose vaccines used in the past had suboptimal potency, while others evoked adequate levels of antitoxin after three primary doses. We concluded that low-dose diphtheria vaccines that have been approved by a national medical products agency can be used for primary vaccination against diphtheria for individuals above 6 years of age. 相似文献
722.
《Vaccine》2023,41(8):1447-1456
Mucosal vaccines offer several advantages over transdermal vaccines, including the ability to acquire systemic and mucosal immunities. Smoking is a huge public health threat and major risk factor for various diseases that exacerbate or prolong respiratory symptoms and conditions. However, its impact on the efficacy of mucosal vaccines remains partially explored. Thus, this study investigates the effects of smoking on mucosal vaccine reactivity by assessing the induction of Th1 immunity, a vital response in infection defense. Cigarette smoke condensate was prepared as a substitute for mainstream smoke. We intranasally administered diphtheria toxoid as an antigen and natural CpG oligonucleotide G9.1, which enhances the Th1-type antibody (Ab) response in a plasmacytoid dendritic cells (pDCs) dependent manner, as an adjuvant to mice to assess the effect of cigarette smoke condensate on Ab responses. The mechanism of its effect was evaluated using human peripheral blood mononuclear cells and their pDC-rich fraction cultured with or without G9.1. In mice, cigarette smoke condensate tended to decrease diphtheria toxoid-specific Ab response, with a higher reduction in Th1-type IgG2 Ab response than in Th2-type IgG1 Ab response. In human peripheral blood mononuclear cells, cigarette smoke condensate significantly reduced the induction of IFN-α production by G9.1. Moreover, G9.1-induced increases in the CD83 expression in pDCs and the CD80 expression in DCs were suppressed via treatment with cigarette smoke condensate. Among the mechanisms suggested were decreased expression of toll-like receptor 9 mRNA, decreased expression of mRNA for IFN regulatory factor 7, and increased CpG methylation of its promoter region. The analysis of Tbet and GATA3 expressions revealed that cigarette smoke condensate exhibits Th1-directed immunostimulatory activity at a steady state but becomes more Th2-directed under G9.1 stimulation. In conclusion, smoking could reduce mucosal vaccine responses by decreasing pDC activation and, consequently, Th1-dominant immunity. 相似文献
723.
汪朝慧胡杰高飞付豹耿争光傅小云 《中华急诊医学杂志》2022,(5):608-612
目的探讨难治性痉挛破伤风患者的临床特点与治疗。方法收集2011年1月至2021年4月遵义医科大学附属医院收治的破伤风患者,根据是否存在难治性痉挛分为难治性痉挛组和普通组,分析比较两组患者一般人口学特点、临床特征、治疗及预后等资料,探讨难治性痉挛破伤风患者的治疗及风险预测因素。结果本研究纳入59例破伤风患者,难治性痉挛组35例(59.32%)、普通组24例(40.68%)。两组患者在性别、年龄、潜伏期、创伤部位比较,差异均无统计学意义(P>0.05)。难治性痉挛破伤风患者均行机械通气,住院时间明显延长、肺部感染率明显增加(P<0.05)。难治性痉挛患者入科第1天多部位肌紧张(肌痉挛/四肢僵硬、颈项强直、角弓反张)发生率较普通组高(P<0.05),预测难治性痉挛的发生时,患者发病初期(入院24 h内)表现为肌痉挛/四肢僵硬+颈项强直+角弓反张的特异度最高。难治性痉挛患者Ⅳ级所占比例明显高于普通组(P<0.05)。48.57%的难治性痉挛破伤风患者需要3种以上镇静药+肌松剂治疗,镇静药使用时间明显延长(P<0.05)。结论难治性痉挛破伤风患者机械通气时间、住院时间明显延长,肺部感染率明显增加,需要长时间大量镇静剂联合肌松剂治疗,发病初期出现多部位肌肉强直的患者出现难治性痉挛发生率较高。 相似文献
724.
《Vaccine》2023,41(13):2208-2213
BackgroundOngoing tetanus cases and sporadic outbreaks of vaccine-preventable diseases associated with routine vaccination programmes remain problems in many low and middle-income countries, including Vietnam. With no human-to-human transmission or natural immunity, tetanus antibody levels indicate both individual risk of tetanus and gaps in vaccination programmes.MethodsTo investigate gaps in immunity to tetanus in Vietnam, a country with a historically high level of tetanus vaccination coverage, tetanus antibodies were measure by ELISA from samples selected from a long-term serum bank, established for the purposes of general-population seroepidemiological investigations in southern Vietnam. Samples were selected from 10 provinces, focussing on age-groups targeted by national vaccination programmes for infants and pregnant women (Expanded Programme on Immunization, EPI, and Maternal and Neonatal Tetanus, MNT).ResultsAntibodies were measured from a total of 3864 samples. Highest tetanus antibody concentrations occurred in children under 4 years old, over 90 % of whom had protective levels. Approximately 70 % of children aged 7–12 years had protective antibody concentrations although there was variation among provinces. For infants and children, there were no significant differences in tetanus protection between males and females, but for adults aged 20–35 years, in five of the ten provinces surveyed, protection against tetanus was higher in females (p < 0.05) who are eligible for booster doses under the MNT programme. In seven of ten provinces, antibody concentrations were inversely related to age (p < 0.01) and protection of older individuals was generally low.ConclusionWidespread immunity to tetanus toxoid is seen in infants and young children consistent with the high coverage rates reported for diptheria tetanus toxoid and pertussis (DTP) in Vietnam. However, the lower antibody concentrations seen in older children and men suggest reduced immunity to tetanus in populations not targeted by EPI and MNT programmes. 相似文献
725.
《Vaccine》2023,41(5):1153-1160
BackgroundImmunogenicity and safety up to 5 years after administration of 1 or 2 doses of quadrivalent meningococcal serogroup A, C, W, and Y tetanus toxoid conjugate vaccine (MenACWY-TT) given alone or with 13-valent pneumococcal conjugate vaccine (PCV13) in children was investigated.MethodsThis phase 3 study randomized healthy 12–24-month-olds to MenACWY-TT at Month 0 (ACWY1d), MenACWY-TT at Months 0 and 2 (ACWY2d), MenACWY-TT and PCV13 at Month 0 (Co-Ad), or PCV13 at Month 0 and MenACWY-TT at Month 2 (PCV13/ACWY). Immune responses 1, 3, and 5 years after primary vaccination were evaluated with serum bactericidal activity using rabbit complement (rSBA) titers ≥ 1:8 and geometric mean titers (GMTs). Evaluation of serious adverse events up to 5 years after primary vaccination are reported.ResultsOf the 802 children randomized in the study, 619 completed the study through Year 5. Immune responses after vaccination declined over time but were higher 5 years after vaccination compared with levels before vaccination. At Year 5, the percentages of children with rSBA titers ≥ 1:8 across all serogroups were 20.5 %?58.6 %, 28.4 %?65.8 %, 23.9 %?52.8 %, and 19.4 %?55.8 % in the ACWY1d, ACWY2d, Co-Ad, and PCV13/ACWY groups, respectively. Comparable antibody persistence at Year 5 was observed for participants receiving 1 or 2 doses of MenACWY-TT, although GMTs were elevated in those who received 2 versus 1 dose. The percentage of children with protective antibody titers at Year 5 was similar in participants who received PCV13 and MenACWY-TT compared with that observed for participants who only received 1 or 2 MenACWY-TT doses. No new safety concerns were identified during the study period.ConclusionAntibody responses persisted in the majority of children up to 5 years after primary vaccination with MenACWY-TT administered in a 1- or 2-dose regimen with or without PCV13, with no new safety concerns identified.ClinicalTrials.gov Identifier NCT01939158; EudraCT number 2013–001083-28. 相似文献